Document Detail


Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma.
MedLine Citation:
PMID:  23389758     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONCLUSION: Postoperative pegylated interferon plus ribavirin is associated with reduced recurrence of HCC in patients with HCV infection. Age, liver cirrhosis, and diabetes mellitus appear to modify this association.
Authors:
Yao-Chun Hsu; Hsiu J Ho; Ming-Shiang Wu; Jaw-Town Lin; Chun-Ying Wu
Related Documents :
22952708 - Hiv and sti prevalence and determinants among male migrant workers in india.
23892238 - Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin...
23392468 - Functional impairment is associated with low bone and muscle mass among persons aging w...
23056308 - Twelve months of routine hiv screening in 6 emergency departments in the paris area: re...
19904648 - Changing masculinities: land-use, family communication and prospects for working with o...
20364538 - Regional and temporal trends in migration among people living with hiv/aids in british ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-05-15
Journal Detail:
Title:  Hepatology (Baltimore, Md.)     Volume:  58     ISSN:  1527-3350     ISO Abbreviation:  Hepatology     Publication Date:  2013 Jul 
Date Detail:
Created Date:  2013-06-26     Completed Date:  2013-08-30     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  8302946     Medline TA:  Hepatology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  150-7     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 American Association for the Study of Liver Diseases.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Carcinoma, Hepatocellular / drug therapy*,  epidemiology,  pathology,  surgery
Chemotherapy, Adjuvant
Cohort Studies
Female
Hepatitis C / complications,  drug therapy*
Humans
Interferon-alpha / therapeutic use*
Liver Neoplasms / drug therapy*,  epidemiology,  pathology,  surgery
Male
Middle Aged
Polyethylene Glycols / therapeutic use*
Postoperative Period
Proportional Hazards Models
Recombinant Proteins / therapeutic use
Recurrence
Ribavirin / therapeutic use*
Taiwan / epidemiology
Chemical
Reg. No./Substance:
0/Interferon-alpha; 0/Polyethylene Glycols; 0/Recombinant Proteins; 0/peginterferon alfa-2a; 49717AWG6K/Ribavirin
Comments/Corrections
Comment In:
Hepatology. 2014 Apr;59(4):1652-3   [PMID:  24038021 ]
Hepatology. 2014 Apr;59(4):1652   [PMID:  23960003 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Neuregulin-1 signalling and antipsychotic treatment : Potential therapeutic targets in a schizophren...
Next Document:  Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with...